Market Place
Sourcing Support
ObsEva Scraps Plans for Uterine Fibroid Candidate
02 Aug 2022 //
FDANEWS
Women`s health firm launches major reorg after ominous FDA note
28 Jul 2022 //
FIERCEPHARMA
ObsEva Announces UK MHRA Marketing Authorization for Yselty in Uterine Fibroids
28 Jun 2022 //
GLOBENEWSWIRE
Theramex Announces EC Marketing Authorization for Yselty in Uterine Fibroids
17 Jun 2022 //
BUSINESSWIRE
ObsEva Presents Data on Oral GnRH Antagonist Linzagolix
25 May 2022 //
GLOBENEWSWIRE
ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix
25 Apr 2022 //
GLOBENEWSWIRE
ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix
25 Apr 2022 //
GLOBENEWSWIRE
ObsEva has Efficacy for Linzagolix 200 mg with ABT, Linzagolix 75 mg without ABT
22 Mar 2022 //
GLOBENEWSWIRE
Theramex, ObsEva Sign Licensing Agreement for Linzagolix in Uterine Fibroids
10 Feb 2022 //
BUSINESSWIRE
ObsEva Provides Update on EU Marketing Authorisation Process for Linzagolix
04 Feb 2022 //
GLOBENEWSWIRE
ObsEva Announces Positive Topline Results for Linzagolix 200 mg in Phase 3
06 Jan 2022 //
GLOBENEWSWIRE
ObsEva Announces Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist
17 Dec 2021 //
GLOBENEWSWIRE
ObsEva Hosts Symposium &Presents Clinical Data Oral GnRH Antagonist Linzagolix
09 Dec 2021 //
GLOBENEWSWIRE
US FDA accepts Obseva’s new drug application for linzagolix
23 Nov 2021 //
PHARMABIZ
ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix
20 Oct 2021 //
GLOBENEWSWIRE
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
13 Oct 2021 //
BIOSPACE
New Drug Application submitted to USFDA for Linzagolix
15 Sep 2021 //
EMPR
ObsEva Announces Submission of New Drug Application to U.S. FDA for Linzagolix
14 Sep 2021 //
GLOBENEWSWIRE
Licensing Agreement for GnRH Antagonist Linzagolix with Bio Genuine in China
02 Sep 2021 //
KISSEI
ObsEva SA Submits Marketing Authorization Application to the EMA or YSELTY®
24 Nov 2020 //
GLOBENEWSWIRE
ObsEva SA Announces Initiation of Phase 3 EDELWEISS 2 and 3 Trials of Linzagolix
09 May 2019 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.